BioNxt Solutions Inc. Advances Patent for Cancer Drug Delivery

BioNxt Solutions Inc. has received a "Readiness to Grant" notification from the Eurasian Patent Organization (EAPO). This involves a comprehensive patent application for sublingual delivery of anticancer drugs treating autoimmune neurodegenerative diseases. Their flagship product, BNT23001, targets multiple sclerosis through a sublingual thin-film formulation of Cladribine.

The formal patent is anticipated shortly, with BioNxt set to make a publication fee payment. The EAPO patent harmonizes application processes across Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Russia, Tajikistan, and Turkmenistan.

CEO Hugh Rogers highlights this as a commercialization milestone, notably as animal bioequivalence studies are about to commence. This development supports BioNxt's strategic patent nationalization in key markets, including the EU, Canada, and the US.